X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SHASUN PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SHASUN PHARMA DISHMAN PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 25.1 123.9 20.2% View Chart
P/BV x 3.3 8.5 39.2% View Chart
Dividend Yield % 0.7 0.2 284.9%  

Financials

 DISHMAN PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SHASUN PHARMA
Mar-14
DISHMAN PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs37494 397.5%   
Low Rs12946 282.7%   
Sales per share (Unadj.) Rs197.8214.2 92.4%  
Earnings per share (Unadj.) Rs21.25.3 397.4%  
Cash flow per share (Unadj.) Rs34.715.8 219.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.81.4 55.6%  
Book value per share (Unadj.) Rs179.953.3 337.2%  
Shares outstanding (eoy) m80.6956.62 142.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 389.8%   
Avg P/E ratio x11.913.1 90.6%  
P/CF ratio (eoy) x7.24.4 164.0%  
Price / Book Value ratio x1.41.3 106.8%  
Dividend payout %9.418.7 50.3%   
Avg Mkt Cap Rs m20,3063,958 513.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,164 247.5%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96112,127 131.6%  
Other income Rs m265229 115.7%   
Total revenues Rs m16,22612,356 131.3%   
Gross profit Rs m4,1031,009 406.6%  
Depreciation Rs m1,091594 183.7%   
Interest Rs m944415 227.5%   
Profit before tax Rs m2,334230 1,015.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10 -366.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-73 -857.5%   
Profit after tax Rs m1,711302 566.4%  
Gross profit margin %25.78.3 309.0%  
Effective tax rate %26.7-31.7 -84.4%   
Net profit margin %10.72.5 430.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,884 160.0%   
Current liabilities Rs m9,5178,456 112.5%   
Net working cap to sales %9.4-13.0 -72.6%  
Current ratio x1.20.8 142.2%  
Inventory Days Days11062 179.3%  
Debtors Days Days35108 32.4%  
Net fixed assets Rs m16,3044,970 328.0%   
Share capital Rs m161113 142.5%   
"Free" reserves Rs m12,9072,875 448.9%   
Net worth Rs m14,5163,020 480.6%   
Long term debt Rs m4,1891,817 230.5%   
Total assets Rs m29,80513,347 223.3%  
Interest coverage x3.51.6 223.5%   
Debt to equity ratio x0.30.6 48.0%  
Sales to assets ratio x0.50.9 58.9%   
Return on assets %8.95.4 165.8%  
Return on equity %11.810.0 117.8%  
Return on capital %17.513.3 131.6%  
Exports to sales %24.846.4 53.5%   
Imports to sales %3.714.2 26.2%   
Exports (fob) Rs m3,9565,622 70.4%   
Imports (cif) Rs m5961,728 34.5%   
Fx inflow Rs m4,9525,843 84.7%   
Fx outflow Rs m6972,173 32.1%   
Net fx Rs m4,2553,669 115.9%   
CASH FLOW
From Operations Rs m2,786398 700.8%  
From Investments Rs m-1,529-1,635 93.5%  
From Financial Activity Rs m-9411,309 -71.9%  
Net Cashflow Rs m31671 444.4%  

Share Holding

Indian Promoters % 61.4 39.2 156.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.6 102.8%  
FIIs % 12.7 17.6 72.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 39.6 55.8%  
Shareholders   46,261 20,750 222.9%  
Pledged promoter(s) holding % 35.8 12.3 291.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PANACEA BIOTECH  BIOCON LTD  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS